Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants

Journal of Medicinal Chemistry

Volumn 46, Issue 14, 2003, Pages 3083-3093

  Tamura, Kunio ^a,d   Kato, Yashiaki ^a   Ishikawa, Akira ^a   Kato, Yasuhara ^a   Himori, Motomu ^a   Yoshida, Mitsutaka ^a   Takashima, Yoshiaki ^a   Suzuki, Tsukasa ^a   Kawabe, Yoshiki ^a   Cynshi, Osamu ^a   Kodama, Tatsuhiko ^b   Niki, Etsuo ^c   Shimizu, Makoto ^d  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^d MIE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (4 METHOXYPHENYL) 3,7 DIHYDROIMIDAZO[1,2 A]PYRAZIN 3 ONE; 4,6 DI TERT BUTYL 2,3 DIHYDRO 2,2 DIPENTYL 5 BENZOFURANOL; 4,6 DI TERT BUTYL 2,3 DIHYDRO 5 BENZOFURANOL; 4,6 DI TERT BUTYL 2,3 DIHYDRO 5 HYDROXY 2,2 DIPENTYLBENZOFURAN; ALPHA TOCOPHEROL; ANTIATHEROGENIC AGENT; ANTIOXIDANT; COPPER; LINOLEIC ACID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROBUCOL; PYRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; AUTOOXIDATION; CHEMOLUMINESCENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYPERLIPIDEMIA; LIPID PEROXIDATION; NONHUMAN; RABBIT;

ALPHA-TOCOPHEROL; ANIMALS; ANTIOXIDANTS; ARTERIOSCLEROSIS; BENZOFURANS; CHEMILUMINESCENT MEASUREMENTS; FREE RADICALS; LINOLEIC ACID; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038460842     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030062a     Document Type: Article

References (39)

1. Steinberg, D.; Parthasarathy, S.; Carew, T. E.; Khoo, J. C.; Witztum, J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 1989, 320, 915-924.
2. Palinski, W.; Rosenfeld, M. E.; Ylä-Herttuala, S.; Gurtner, G. C.; Socher, S. S.; Butler, S. W.; Parthasarathy, S.; Carew, T. E.; Steinberg, D.; Witztum, J. L. Low-density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 1372-1376.
3. Witztum, J. L.; Steinberg, D. Role of oxidized low-density lipoprotein in atherogenesis. J. Clin. Invest. 1991, 88, 1785-1792.
4. Björkhem, I.; Henriksson-Freyschuss, A.; Breuer, O.; Diczfalusy, U.; Berglund, L.; Henriksson, P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler. Thromb. 1991, 11, 15-22.
5. Mao, S. J. T.; Yates, M. T.; Parker, R. A.; Chi, E. M.; Jackson, R. L. Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29, 311) that does not lower serum cholesterol. Arterioscler. Thromb. 1991, 11, 1266-1275.
6. Sparrow, C. P.; Doebber, T. W.; Olszewski, J.; Wu, M. S.; Ventre, J.; Stevens, K. A.; Chao, Y. S. Low-density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′diphenyl-phenylenediamine. J. Clin. Invest. 1992, 89, 1885-1891.
7. Tangirala, R. K.; Casanada, F.; Miller, E.; Witztum, J. L.; Steinberg, D.; Palinski, W. Effect of the antioxidant N,N′diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 1625-1630.
8. Kita, T.; Nagano, Y.; Yokode, M.; Ishii, K.; Kume, N.; Ooshima, A.; Yoshida, H.; Kawai, C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 5928-5931.
9. Carew, T. E.; Schwenke, D. C.; Steinberg, D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low-density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 7725-7729.
10. Nagano, Y.; Nakamura, T.; Matsuzawa, Y.; Cho, M.; Ueda, Y.; Kita, T. Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit - long-term antiatherogenic effect and effects on established plaques. Atherosclerosis 1992, 92, 131-140.
11. Daugherty, A.; Zweifel, B. S.; Schonfeld, G. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br. J. Pharmacol. 1989, 98, 612-618.
12. Sasahara, M.; Raines, E. W.; Chait, A.; Carew, T. E.; Steinberg, D.; Wahl, P. W.; Ross, R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. J. Clin. Invest. 1994, 94, 155-164.
13. Walldius, G.; Erikson, U.; Olsson, A. G.; Bergstrand, L.; Hådell, K.; Johansson, J.; Kaijser, L.; Lassvik, C.; Mölgaard, J.; Nilsson, S.; Schafer-Elinder, L.; Stenport, G.; Holme, I. The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST). Am. J. Cardiol. 1994, 74, 875-883.
14. Johansson, J.; Olsson, A. G.; Bergstrand, L.; Elinder, L. S.; Nilsson, S.; Erikson, U.; Mölgaard, J.; Holme, I.; Walldius, G. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 1049-1056.
15. Reinoehl, J.; Frankovich, D.; Machado, C.; Kawasaki, R.; Baga, J. J.; Pires, L. A.; Steinman, R. T.; Fromm, B. S.; Lehmann, M. H. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am. Heart J. 1996, 131, 1184-1191.
16. Miller, N. E. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am. Heart J. 1987, 113, 589-597.
17. Gotoh, N.; Shimizu, K.; Komuro, E.; Tsuchiya, J.; Noguchi, N.; Niki, E. Antioxidant activities of probucol against lipid peroxidations. Biochim. Biophys. Acta 1992, 1128, 147-154.
18. Rimm, E. B.; Stampfer, M. J.; Ascherio, A.; Giovannucci, E.; Colditz, G. A.; Willett, W. C. Vitamin E consumption and the risk of coronary heart disease in men. N. Engl. J. Med. 1993, 328, 1450-1456.
19. Blot, W. J.; Li, J.; Taylor, P. R.; Guo, W.; Dawsey, S.; Wang, G.; Yang, C. S.; Zheng, S.; Gail, M.; Li, G.; Yu, Y.; Liu, B.; Tangrea, J.; Sunn, Y.; Liu, F.; Fraumeni, J. F., Jr.; Zhang, Y.; Li, B. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl. Cancer Inst. 1993, 85, 1483-1492.
20. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect ofvitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 1994, 330, 1029-1035.
21. GISSI-Prevenzione Investigators. Dietary supplementation with n-3polyunnsatuurated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354, 447-455.
22. Bowry, V. W.; Ingold, K. U.; Stocker, R. Vitamin E in human low-density lipoprotein: When and how this antioxidant becomes a pro-oxidant. Biochem. J. 1992, 288, 341-344.
23. Bowry, V. W.; Stocker, R. Tocopherol-mediated peroxidation. The prooxidant effect ofvitamin E on the radical-initiated oxidation ofhuman low-density lipoprotein. J. Am. Chem. Soc. 1993, 115, 6029-6044.
24. Niu, X.; Zammit, V.; Upston, J. M.; Dean, R. T.; Stocker, R. Coexistence of oxidized lipids and alpha-tocopherol in all lipoprotein density fractions isolated from advanced human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 1708-1718.
25. Upston, J. M.; Terentis, A. C.; Morris, K.; Keaney, Jr. J. F.; Stocker, R. Oxidized lipid accumulates in the presence of alphatocopherol in atherosclerosis. Biochem. J. 2002, 363, 753-760.
26. Cynshi, O.; Kawabe, Y.; Suzuki, T.; Takashima, Y.; Kaise, H.; Nakamura, M.; Ohba, Y.; Kato, Y.; Tamura, K.; Hayasaka, A.; Higashida, A.; Sakaguchi, H.; Takeya, M.; Takahashi, K.; Inoue, K.; Noguchi, N.; Niki, E.; Kodama, T. Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 10123-10128.
27. Esterbauer, H.; Gebicki, J.; Puhl, H.; Jürgens, G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic. Biol. Med. 1992, 13, 341-390.
28. Burton, G. W.; Doba, T.; Gabe, E. J.; Hughes, L.; Lee, F. L.; Prasad, L.; Ingold, K. U. Autoxidation of biological molecules. 4. Maximizing the antioxidant activity ofphenols. J. Am. Chem. Soc. 1985, 107, 7053-7065.
29. Ingold, K. U.; Burton, G. W.; Foster, D. O.; Zuker, M.; Hughes, L.; Lacelle, S.; Lusztyk, E.; Slaby, M. A new vitamin E analogue more active than alpha-tocopherol in the rat curative myopathy bioassay. FEBS Lett. 1986, 205, 117-120.
30. Stokker, G. E.; Deana, A. A.; deSolms, S. J.; Schultz, E. M.; Smith, R. L.; Cragoe, E. J., Jr.; Baer, J. E.; Ludden, C. T.; Russo, H. F.; Scriabine, A.; Sweet, C. S.; Watson, L. S. 2-(Aminomethyl)phenols, a new class of saluretic agents. 1. Effects of nuclear substitution. J. Med. Chem. 1980, 23, 3, 1414-1427.
31. Einhorn, A.; Mauermayer, T. N-Methylolchloracetamid. Justus Liebigs Ann. Chem. 1905, 343, 282-283.
32. Stokker, G. E.; Schultz, E. M. The use of sterically hindered benzylamines in the Sommelet reaction. Synth. Commun. 1982, 12, 847-853.
33. Zambias, R. A.; Caldwell, C. G.; Kopka, I. E.; Hammond, M. L. A convenient synthesis of 4-tert-butyl-5-benzofuranols and dihydrobenzofuranols. J. Org. Chem. 1988, 53, 4135-4137.
34. Nakano, M. Determination of superoxide radical and singlet oxygen based on chemiluminescence of Luciferin analogues. Methods Enzymol. 1990, 186, 585-591.
35. Noguchi, N.; Iwaki, Y.; Takahashi, M.; Komuro, E.; Kato, Y.; Tamura, K.; Cynshi, O.; Kodama, T.; Niki, E. 2,3-Dihydro-5hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: design and evaluation as a novel radical-scavenging antioxidant against lipid peroxidation. Arch. Biochem. Biophys. 1997, 342, 236-243.
36. Noguchi, N.; Okimoto, Y.; Tsuchiya, J.; Cynshi, O.; Kodama, T.; Niki, E. Inhibition of oxidation of low-density lipoprotein by a novel antioxidant, BO-653, prepared by theoretical design. Arch. Biochem. Biophys. 1997, 347, 141-147.
37. Noguchi, N.; Niki, E. Phenolic antioxidants: a rationale for design and evaluation of novel antioxidant drug for atherosclerosis. Free Radic. Biol. Med. 2000, 28, 1538-1546.
38. Havel, R. J.; Eder, H. E.; Bragdon, J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin. Invest. 1955, 34, 1345-1353.
39. Cynshi, O.; Takashima, Y.; Suzuki, T.; Kawabe, Y.; Ohba, Y.; Kodama, T. Characterization of aggregated low-density lipoproteins induced by copper-catalyzed oxidation. J. Atheroscler. Thromb. 1994, 1, 87-97.